RT Journal
A1 Richter WO, Schwandt P
T1 DIsruption and meaning
JF JAMA
JO JAMA
YR 1998
FD August 19
VO 280
IS 7
SP 603
OP 604
DO 10-1001/pubs.JAMA-ISSN-0098-7484-280-7-jbk0819
UL http://dx.doi.org/10-1001/pubs.JAMA-ISSN-0098-7484-280-7-jbk0819
AB 
To the Editor.—In 1988, the European Atherosclerosis Society recommended a therapeutic goal for cholesterol of 5.2 mmol/L (200 mg/dL) and for low-density lipoprotein cholesterol of 3.5 mmol/L (135 mg/dL) in patients with coronary heart disease.1 These therapeutic goals preferably should be reached by dietary measures, but if hypercholesterolemia persists, drug therapy should be initiated. We wondered whether these recommendations, widely distributed in European countries, are accepted in clinical practice and have been influenced by the publication of the results of several secondary intervention studies with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors from 1990 to 1994 and new, more rigorous guidelines.2- 3